tiprankstipranks
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
US Market
RARE
Ultragenyx Pharmaceutical
RESEARCH TOOLSreports
Want to see RARE full AI Analyst Report?

Ultragenyx Pharmaceutical (RARE) Income Statement

1,215 Followers

Ultragenyx Pharmaceutical Income Statement

Last quarter (Q4 2025), Ultragenyx Pharmaceutical's total revenue was $207.00M, an increase of 25.55% from the same quarter last year. In Q4, Ultragenyx Pharmaceutical's net income was $-129.00M. See Ultragenyx Pharmaceutical’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 673.00M$ 560.23M$ 434.25M$ 363.33M$ 351.41M
Gross Profit
$ 564.00M$ 483.50M$ 389.04M$ 335.01M$ 335.40M
Operating Expenses
$ 1.10B$ 1.02B$ 958.25M$ 983.93M$ 717.13M
Depreciation and Amortization
$ 35.00M$ 35.54M$ 26.01M$ 18.22M$ 13.24M
EBITDA
$ -500.00M$ -469.00M$ -516.45M$ -640.49M$ -410.32M
Operating Income
$ -535.00M$ -535.97M$ -569.21M$ -648.92M$ -381.74M
Other Income/Expenses
$ -36.00M$ -31.61M$ -39.26M$ -52.81M$ -71.24M
Pretax Income
$ -571.00M$ -567.59M$ -608.46M$ -701.73M$ -452.98M
Net Income
$ -575.00M$ -569.18M$ -606.64M$ -707.42M$ -454.02M
Per Share Metrics
Basic EPS
$ -5.83$ -6.29$ -8.25$ -10.12$ -6.70
Diluted EPS
$ -5.83$ -6.29$ -8.25$ -10.12$ -6.70
Weighted Average Shares Outstanding
 98.60M 90.54M 73.54M 69.91M 67.80M
Weighted Average Shares Outstanding (Diluted)
 98.60M 90.54M 73.54M 69.91M 67.80M
Currency in USD

Ultragenyx Pharmaceutical Earnings and Revenue History